News

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...
Hudson Institute's leadership in RNA research has again been recognised, this time with a significant research grant from the Victorian government.Dr ...
The Allan Labor Government is backing breakthrough research that has potential to save millions of lives worldwide and position Victoria as a global ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Technology can be harnessed to design novel and enhanced molecules that address challenges in biotechnology or medicine. Australian researchers, including those at the Charles Perkins Centre at the ...
US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...
The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its ...
The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.
The US Food and Drug Administration granted full approval to Moderna's Spikevax vaccine and the company is hopeful of releasing the updated version for the 2025-26 flu season ...